Refine your search
Collections
Co-Authors
Journals
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Al-Majed, A. A.
- Anodic Polaroqraphic Determination of Isradipine in Pharmaceutical Formulations
Abstract Views :162 |
PDF Views:0
Authors
Affiliations
1 Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh-11451, SA
1 Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh-11451, SA
Source
Scientia Pharmaceutica, Vol 72, No 2 (2004), Pagination: 131-142Abstract
The anodic behaviour of isradipine was studied using cyclic voltammetry (CV), direct current (DCt) and differential-pulse (DPP) polarography. Isradipine exhibited well-defined anodic polarographic waves over the pH range of 4-8 in Britton-Robinson buffer (BRb). At pH 6, the analytical pH, the diffusion-current constant (Id) was 2.12 ± 0.42 (n = 4). The oxidation potential is -0.1 0 V vs. Ag/AgCI reference electrode with correlation coefficients of 0.9977 and 0.9948 in the DCt and DPP modes, respectively. The current-concentration plots were rectilinear over the ranges 5-14 μg/ml and 2.4-12 μg/ml using the DCt and DPP modes, respectively. The lower detection limit was 1.12 μg/ml (3.02 × 10-6M) adopting the DPP mode. The proposed method was applied to commercial tablets and capsules, the % recoveries were 100.52 ± 1.267 and 99.4 ± 0.87 (n = 6) for the tablets and 101.3 ± 1.57 and 100.7 ± 2.10 (n = 6) for the capsules adopting both DCt and DPP modes, respectively. The number of electrons involved in the electrode process was accomplished and a proposal of the electrode reaction was presented.Keywords
Isradipine; Anodic Polarography; Dosage Forms.References
- Parfitt K. (Ed.). Martindale, The Complete Drug Reference 33rd Ed. The Pharmaceutical Press, Massachusetts 2002, 916-18.
- The British Pharmacopoeia. The Pharmaceutical Press, London 2000, 768-44.
- The United States Pharmacopoeia. The United States Pharmacopeial Convention, Rockville, MD 2001, 941-47.
- Mieclarek J. Normal-phase TLC separation of enantiomers of 1,4-dihydropyridine derivatives. Drug Dev. Ind. Pharm. 2001; 27: 175-79.
- Abd-Elghany M.F., Abd-Elkawy M., El-Zeany B., Stewart J.T. A stability-indicating high performance liquid chromatographic quantitation of isradipine in the presence of its degradation products. J. Planar Chromatogr. Mod. TLC 1996; 9: 290-92.
- Maurer H.M., Arit J.W. Screening procedure for detection of dihydropyridine calcium channel blockers metabolism in urine as part of a systemic toxicological analysis procedure for acidic compounds by gas-chromatography (GC-MS) after extractive methylation. J. Anal. Toxicol. 1999; 23: 73-80.
- Jean C., Laplanche R. Assay of isradipine and of its major metabolites in biological fluids by capillary gas chromatography and chemical-ionisation mass spectrometry. J. Chromatogr. B. 1988; 72: 61-69.
- Christensen H.R., Angelo H.R., Skajaa K. Determination of isradipine and its metabolite in serum by capillary column gas chromatography with nitrogen selective detection. J. Chromatogr. B. 1992; 112: 161-65.
- Rask H.S., Angelo H.R., Christensen H.R. Enantioselective determination of isradipine in human serum using chiral stationary phase liquid chromatography and gas chromatography with nitrogen selective detection. Chirality, 1998; 10: 808-812.
- Tesarova E., Gilar M., Hobza P., Kabelac M., Deyl Z., Smolkova-Keulemanosova E. Correlation between structure of dihydropyridine calcium antagonists and their retention behaviour and enantioseparation on the β-cyclodextrin stationary phase in HPLC. J. High Reslut. Chromatogr. 1995; 18: 597-601.
- Okamoto Y., Aburatani R., Hata K., Honda M., lnotsume N., Nakano M. Optical resolution of dihyropyridine enantiomers by high performance liquid chromatography using phenylcarbamates as a chiral stationary phase. J. Chromatogr. 1990; 513: 375-78.
- Takamura K., Kusus F., Abdel-Wadood H., El-Rabbat N., Saleh G., Refaat I. Redox properties of isradipine and its electrochemical detection in the HPLC determination of the compound in human serum. Biomed. Chromatogr. 2000; 14: 453-58.
- Bartlett M.G., Spell J.C, Mathis P.S., Abdel-Ghany M.F., El-Zeany B.E., Abdel-Kawy M., Stewart J.T. Determination of degradation products from calcium-channel blocker isradipine. J. Pharm. Biomed. Anal. 1998; 18: 335-45.
- Abdel-Ghany M.F., El-Zeany B.E., Abdel-Kawy M., Stewart J.T. A stability-indicatng high performance liquid chromatographic assay of isradipine in pharmaceutical preparations. Anal. Lett. 1996; 29: 1157-1165.
- Kuesters E., Dosenbach C., Geber G. Enantiomeric separation of isradipine and related compounds by liquid chromatography with a chiral stationary phase. J. High Resolut. Chromatogr. 1991; 14: 769-771.
- Boutagy J., Ramble F., Dunagan F. Determination of isradipine and the oxidative pyridine metabolite in human plasma by high performance liquid chromatography. J. Chromatogr. 1989; 79: 483-88.
- Al-Suwyeh S.A., Quick, simple and sensitive HPLC method for the determination of isradipine in plasma and its application in pharmacokinetic studies. Anal. Lett. 2002; 35: 1205-1213.
- Belal F., Al-Majed A., Julkhuf S. Voltammetric determination of isradipine in dosage forms and spiked human urine and plasma. J. Pharm. Biomed. Anal. 2003; 31 : 989-98.
- Albini A. and Fasani E., editor, Drugs Photochemistry and Photostability. The Royal Society of Chemistry, Cambridge 1998, 21-23.
- Heyrovsky J., Zuman P. Practical Polarography. Academic Press, New York, 1965, 163.
- Meites L., Israel Y. The calculation of electrochemical kinetic parameters from polarographic current-potential curves. J. Am. Chem. Soc. 1961; 83: 4903-4907.
- Proszt J., Cieleszky V., Gyijrbiro K. Polarographie. Akademiai Kiado, Budapest 1967,385-91.
- HeyrovskyJ., Kuta J. Principles of Polarography. Academic Press, New York, 1968, 163-65.
- Squella J.A., Barnafi E., Perna S., Nunez-Vergara L.J. Nifepidine: differential pulse polarography and photodecomposition. Talanta, 1989; 36: 363-367.
- Miller J.C., Miller J.N. Statistics for Analytical Chemistry. John Wiley and Sons, New York 1983,83-87.
- Effect of Prolonged Vigabatrin Treatment on Hematological and Biochemical Parameters in Plasma, Liver and Kidney of Swiss Albino Mice
Abstract Views :586 |
PDF Views:0
Authors
Affiliations
1 Department of Pharmacology, College of Pharmacy, King Saud University, P O Box 2457, Riyadh 11451, SA
1 Department of Pharmacology, College of Pharmacy, King Saud University, P O Box 2457, Riyadh 11451, SA
Source
Scientia Pharmaceutica, Vol 70, No 2 (2002), Pagination: 135-145Abstract
We have evaluated vigabatrin (γ-vinyl γ-aminobutyric acid), an irreversible inhibitor of γ-aminobutyric acid (GABA)-transaminase responsible for GABA degradation, for its effects on food consumption, body weight changes, fluid intake, changes in hematological and biochemical parameters in plasma liver and kidney of Swiss albino mice. Mice received vigabatrin 0.26% wlv chronically in drinking water for 7, 14 and 21 days. Changes in all the parameters were recorded after 7, 14 and 21 days respectively in different groups. Food consumption was comparable to the control group with minor fluctuations. The body weight declined significantly but only after 3-week treatment with no appreciable change in organ indices or relative organ indices. There were essentially no adverse effects on hematological parameters (RBC, WBC, HGB, neutrophils, eosinophils, monocytes, lymphocytes and basophils) with this treatment. However, there was a decrease in monocyte counts during the first week and an increase in the neutrophil counts during the third week of vigabatrin treatment. In one part plasma biochemical parameters like AST, ALT, CK-MB, creatinine, glucose and urea were also assessed with the same dose regimen. It was observed that only CK-MB and GPT activity levels were altered slightly significantly and are thought to be a result of cross enzyme inhibitions. In this experiment it was observed that lipid peroxide levels measured, as malondialdehyde did not change appreciably in both liver and kidney tissues. However, the levels of glutathione (non-protein sulfhydryl; GSH) declined significantly in comparison to control in liver and kidney. A comparison of level of GSH in liver and kidney shows that this depletion was at early time points in the former. The depletion of GSH suggests the possible involvement of GSH in detoxification process and corroborates its role in protection.Keywords
Vigabatrin, Hematology, Plasma, Liver, Kidney, BiochemistryReferences
- Bartoli A., Gatti G.,. Cipolla G., Barzaghi N., Veliz G., Fattore C., Mumford J., Perucca E. (1997), Epilepsia; 38:702-707.
- Ferkany J. W., Smith L. A., Scifert W.E., Caprioli R.M., Enna S.J. (1978), Life Sci. 22: 2121-2128.
- Bertilsson L., Suria A,, Costa E. (1976), Nature (London). 260: 540-541.
- Okada Y., Tanguchi H., Schimada C. (1976), Science. 194: 620-622.
- Raza M., Al-Shabanah O.A., Al-Harbi M.M., El-Hadiyah T.M.H., Qureshi S. (2000), Saudi Pharm. J. 8(4): 164-174.
- Raza M., Al-Shabanah O.A., Al-Harbi M.M., El-Hadiyah T.M.H., Qureshi S. (2000), Sci. Pharm. 68: 379-388.
- Raza M., Al-Shabanah O. A., El-Hadiyah T.M., Al-Bekairi A.M., Qureshi S. (2001), Sci. Pharm. 69: 203-210.
- Mazurkiewicz M., Sirvio J., Riekkinen P.Sr. (1992), Epilepsy Res. 12: 231-237.
- Ohkawa H., Ohishi N., Yagi K. (1979), Anal. Biochem. 95: 351-358.
- Sedlak J., Lindsay R.H., (1968), Anal. Biochem.25: 192-205.
- Huot S., Palfreyman M.G. (1982), Pharmacol. Biochem. Behav. 17: 99-106.
- Singewald N., Pfitscher A., Philippu A. (1992), Naunyn Schmiedebergs Arch. Pharmacol. 345: 181-186.
- Gibson J.P., Yarrigton J.T., Loudy D.E., Gerbig C.G., Hurst G.H., Newberne J.W. (1990), Toxicol. Pathol. 18: 225-238.
- Frisk-Holmberg M., Kerth P., Meyer P. (1989), Br. J. Clin. Pharmacol. 27(suppl 1): 23s-25s.
- Jung M.J., Lippert B., Metcalf B.W., Bohlen P., Schechter P.J. (1977), J. Neurochem. 29: 797-802.
- Ben-Menachem E., Persson L.I., Schechter P.J., Haegele K.D., Huebert N., Hardenberg J., Dahlgren L., Mumford J.P. (1989), Br. J. Clin. Pharmacol. 27 (suppl. 1): 79s-85s.
- Richens A. (1991), J. Child. Neurol. (Suppl. 2): S7-S10.
- Cocito L., Maffini M., Loeb C. (1993), Seizure. 2: 301-307.
- Vogt H., Kramer G. (1995), Schweiz. Med. Wochenschr. 125: 125-132.
- Herranz J.L., Arteaga R., Farr I.N., Valdizan E., Beaumont D., Armijo J.A. (1991), J. Child. Neurol. (Suppl), 2: S45-S51.
- Kaplan A,, Szabo L.L. (1983), Enzymes In: Clinical Chemistry: Interpretations and Techniques. Lea and Febiger, Philadelphia, 2nd edition, pp. 173-218.
- Foletti G.B., Delisle M.C., Bachmann C. (1995), Epilepsia. 38: 804-809.
- Enna S.J. (1981). Neuropharmachemical and clinical aspects of γ-aminobutyric acid (GABA). In: Neuropharmacolgy of central and behavioral disorders. Ed. Palmer G. Academic Press, New York, Pp. 507-537.
- Gilon P., Bertrand G., Loubatieres-Mariani M.M., Remacle C., Hanquin J.C. (1991), Endocrinology. 129: 2521-2529.
- Kosower N.S., Kosower E.M. (1983), Glutathione and cell membrane thiol status. In: Functions of glutathione. Eds. Larsson A., Orrenius S., Holmgren A., Mannervick B. Raven Press, New York Pp. 307-315.
- Bellomo G., Orrenius S. (1985), Hepatology, 5: 876-882.
- Rogers C., Brown A,, Szabo S. (1988), Dig. Dis. Sci. 33: 324-329.
- Szabo S., Trier J.S., Frankel P.W. (1981), Science. 214: 200-202.
- Raza M., Al-Bekairi A.M., Ageel A.M., Qureshi S. (1997), Pharmacol. Res. 35: 153-157.